Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Garmin Ltd. (GRMN) Price & Performance

Cassava Sciences IncTrade
Garmin Ltd.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Garmin Ltd. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Garmin Ltd. trades at $309.51 (market cap $60.39B). The key difference: Garmin Ltd. is far larger — about 1264.7× Cassava Sciences Inc's market cap, and Garmin Ltd. pays a 1.34% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAGRMN
Market Cap
$47.75M$60.39B
Sector
HealthTechnology
52-Week High
$4.64$313.16
52-Week Low
$0.87$187.10
Enterprise Value
-$34.93M$57.91B
Dividend Yield
1.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Garmin Ltd.

Garmin (GRMN) trades at $310.89, up 2.96% today and near its all-time high, with a bullish technical trend supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.81 versus $2.30 expected, and raised full-year guidance. Revenue growth is robust, driven by the fitness segment, with 2025 revenue at $7.25 billion and net income margin of 24.47%.

Outlook is positive due to sustained demand for wearables and upward revisions, but risks include rich valuations (P/E of 32.08) and potential growth deceleration. Analyst consensus is cautious with 74% hold ratings, though the price target of $318.67 suggests modest upside. Investors should weigh strong fundamentals against high expectations.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN